Chemo before and after surgery for borderline resectable pancreatic cancer
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy drugs (irinotecan liposome, 5-FU, leucovorin, and oxaliplatin) given before and after surgery for people with pancreatic cancer that is on the border of being removable. The goal is to see if this treatment helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer is considered "borderline resectable" by your doctor, meaning it’s on the edge of being removable with surgery.
- You have at least one tumor that can be measured on a scan.
- You have not received any previous cancer treatment (like chemotherapy, radiation, or targeted therapy).
- You are in good physical condition (ECOG score 0 or 1) and expected to live at least 3 more months.
- Your major organs (liver, kidneys, bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (FOLFIRINOX and gemcitabine plus TAMP) given before surgery for borderline resectable pancreatic cancer. The goal is to shrink the tumor and make surgery more successful.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Hear when a new Borderline Resectable Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.